HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
The clinical trial will be conducted at 19 sites with 10,335 participants across India
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Strong topline growth driven by solid performance across key brands.
Decision on EU marketing authorisation for this population expected by September 2024
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Subscribe To Our Newsletter & Stay Updated
